Vertex Pharmaceuticals Incorporated NMS · VRTX
Price alert —
Sign in to get a one-time email the moment VRTX crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · VRTX
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3.0B | $1.0B | $1.1B | $1.3B | 34.5% | 38.1% |
| 2025-12-31 | $3.2B | $1.2B | $1.1B | $0.3B | 37.3% | 35.4% |
| 2025-09-30 | $3.1B | $1.1B | $1.2B | $1.1B | 35.2% | 40.3% |
| 2025-06-30 | $3.0B | $1.0B | $1.2B | $0.9B | 34.8% | 38.9% |
| 2025-03-31 | $2.8B | $0.6B | $1.0B | $0.8B | 23.3% | 37.2% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare VRTX vs peers
Line VRTX up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with VRTX
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-04 | 4.47 | 4.31 | +3.8% | -1.3% |
| 2026-02-12 | 5.03 | 5.15 | -2.3% | +5.7% |
| 2025-11-03 | 4.80 | 4.58 | +4.9% | -1.0% |
| 2025-08-04 | 4.52 | 4.25 | +6.3% | -20.6% |
| 2025-05-05 | 4.06 | 4.29 | -5.4% | -10.0% |
| 2025-02-10 | 3.98 | 4.02 | -1.0% | -3.1% |
| 2024-11-04 | 4.38 | 4.13 | +6.0% | +5.7% |
| 2024-08-01 | -12.83 | -11.75 | -9.2% | -2.2% |
| 2024-05-06 | 4.76 | 4.06 | +17.3% | +1.9% |
| 2024-02-05 | 4.20 | 4.09 | +2.8% | -3.0% |
| 2023-11-06 | 4.08 | 3.97 | +2.7% | -1.9% |
| 2023-08-01 | 3.89 | 3.88 | +0.1% | +3.1% |
| 2023-05-01 | 3.05 | 3.00 | +1.6% | +0.3% |
| 2023-02-07 | 3.76 | 3.51 | +7.0% | -4.9% |
| 2022-10-27 | 4.01 | 3.64 | +10.1% | +9.0% |
| 2022-08-04 | 3.60 | 3.50 | +2.8% | +4.8% |
| 2022-05-05 | 3.52 | 3.54 | -0.4% | -4.7% |
| 2022-01-26 | 3.37 | 3.29 | +2.5% | +0.7% |
| 2021-11-02 | 3.56 | 3.07 | +15.8% | +4.2% |
| 2021-07-29 | 3.11 | 2.38 | +30.7% | +0.6% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| VRTX ★ | $122B | 28.6 | 22.6 | 10.0 | 23.4 | 6.3 | 54.4% | 7.8% | 61.4% | 2.28% |
| LLY | $1,047B | 41.8 | 26.1 | — | 29.3 | 33.6 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $396B | 32.9 | 19.5 | 0.9 | 17.5 | 3.8 | 19.5% | 0.4% | 61.5% | 5.74% |
| JNJ | $604B | 29.1 | 19.5 | 6.2 | 18.1 | 7.4 | 68.1% | 6.6% | -1.0% | — |
| MRK | $312B | 35.6 | 13.1 | — | 11.9 | 6.8 | 76.7% | 4.9% | — | 4.50% |
| ABBV | $452B | 124.9 | 15.7 | 7.2 | 17.1 | -68.0 | 72.0% | 12.4% | -46.2% | 4.60% |
| PFE | $142B | 19.1 | 8.8 | — | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.70% |
| TMO | $194B | 28.7 | 19.2 | — | 20.9 | 3.7 | 40.9% | 6.2% | 11.3% | 2.84% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 51.24%
| Holder | Shares | % out |
|---|---|---|
| Capital World Investors | 25,368,124 | 10.00% |
| Blackrock Inc. | 23,969,517 | 9.44% |
| Capital Research Global Investors | 21,125,964 | 8.32% |
| Vanguard Capital Management LLC | 16,512,810 | 6.51% |
| State Street Corporation | 11,730,139 | 4.62% |
| Invesco Ltd. | 7,892,611 | 3.11% |
| JPMORGAN CHASE & CO | 7,033,156 | 2.77% |
| Geode Capital Management, LLC | 6,139,621 | 2.42% |
| Vanguard Portfolio Management LLC | 5,145,609 | 2.03% |
| Capital International Investors | 5,126,077 | 2.02% |
Insider activity · 90d
3 buys / 12 sells · ratio 0.25 · Finnhub
- McKechnie Duncan SELL 11,001 @ $519.00
- Tatsis Ourania SELL 45,321 @ $524.99
- Liu Joy SELL 19,131 @ $502.71
- Bozic Carmen SELL 15,933 @ $462.17
- Bozic Carmen SELL 21,015 @ $450.00
- Liu Joy SELL 19,959 @ $439.91
- Bozic Carmen SELL 22,760 @ $450.00
- Bunnage Mark E. SELL 7,284 @ $453.45
- Bozic Carmen SELL 24,734 @ $453.45
- Bozic Carmen SELL 26,088 @ $450.00
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-07-17 | FORM 4 | view · |
| 4 | 2026-07-17 | FORM 4 | view · |
| 4 | 2026-07-07 | FORM 4 | view · |
| 4 | 2026-07-07 | FORM 4 | view · |
| 8-K | 2026-07-07 | 8-K | view · |
| 4 | 2026-07-06 | FORM 4 | view · |
| 4 | 2026-06-30 | FORM 4 | view · |
| 4 | 2026-06-23 | FORM 4 | view · |
| 4 | 2026-06-17 | FORM 4 | view · |
| 4 | 2026-06-09 | FORM 4 | view · |
| 4 | 2026-06-03 | FORM 4 | view · |
| 4 | 2026-06-02 | FORM 4 | view · |
| 4 | 2026-05-19 | FORM 4 | view · |
| 4 | 2026-05-19 | FORM 4 | view · |
| 4 | 2026-05-14 | FORM 4 | view · |
| 8-K | 2026-05-13 | 8-K | view · |
| 4 | 2026-05-05 | FORM 4 | view · |
| 4 | 2026-05-05 | FORM 4 | view · |
| 4 | 2026-05-05 | FORM 4 | view · |
| 4 | 2026-05-05 | FORM 4 | view · |
| 4 | 2026-05-05 | FORM 4 | view · |
| 4 | 2026-05-05 | FORM 4 | view · |
| 4 | 2026-05-05 | FORM 4 | view · |
| 4 | 2026-05-05 | FORM 4 | view · |
| 4 | 2026-05-05 | FORM 4 | view · |
| 4 | 2026-05-05 | FORM 4 | view · |
| 10-Q | 2026-05-05 | 10-Q | view · |
| 8-K | 2026-05-04 | 8-K | view · |
| 8-K | 2026-04-29 | 8-K | view · |
| 4 | 2026-04-17 | FORM 4 | view · |
| 4 | 2026-04-17 | FORM 4 | view · |
| 4 | 2026-04-17 | FORM 4 | view · |
| 4 | 2026-04-03 | FORM 4 | view · |
| DEF 14A | 2026-04-02 | DEF 14A | view · |
| 4 | 2026-03-31 | FORM 4 | view · |
| 8-K | 2026-03-31 | 8-K | view · |
| 4 | 2026-03-17 | FORM 4 | view · |
| 4 | 2026-03-13 | FORM 4 | view · |
| 4 | 2026-03-06 | FORM 4 | view · |
| 4 | 2026-03-04 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 4 | 2026-03-02 | FORM 4 | view · |
| 4 | 2026-02-26 | FORM 4 | view · |
| 4 | 2026-02-26 | FORM 4 | view · |
| 4 | 2026-02-26 | FORM 4 | view · |
| 4 | 2026-02-26 | FORM 4 | view · |
| 4 | 2026-02-26 | FORM 4 | view · |
| 4 | 2026-02-26 | FORM 4 | view · |
| 4 | 2026-02-26 | FORM 4 | view · |
| 4 | 2026-02-26 | FORM 4 | view · |
| 4 | 2026-02-26 | FORM 4 | view · |
| 4 | 2026-02-26 | FORM 4 | view · |
| 4 | 2026-02-26 | FORM 4 | view · |
| 4 | 2026-02-23 | FORM 4 | view · |
| 4 | 2026-02-19 | FORM 4 | view · |
| 4 | 2026-02-19 | FORM 4 | view · |
| 4 | 2026-02-19 | FORM 4 | view · |
| 4 | 2026-02-19 | FORM 4 | view · |
| 4 | 2026-02-19 | FORM 4 | view · |
About VRTX
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule…
Options picks · VRTX
ITM + OTM ideas from the latest scanLoading…
Congress trades · VRTX
STOCK Act disclosuresLoading…
SEC filings & insiders · VRTX
EDGAR · liveLoading…
Holders · VRTX
Institutions & insider activityLoading…